EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High cure rates of Mycoplasma genitalium following empiric treatment with azithromycin alongside frequent detection of macrolide resistance in Austria

David Chromy, Lisa Starossek, Katharina Grabmeier-Pfistershammer, Sarah Adamek, Felix Maischack, Stefanie Sammet, Birgit Sadoghi, Georg Stary, Birgit Willinger, Wolfgang Weninger, Stefan Esser, Athanasios Makristathis und 1 weitere

Infection · 2024-10 · 52 (5) · 1921-1930

DOI: 10.1007/s15010-024-02261-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Infection, online erschienen am 22.04.2024. Verfasst von David Chromy und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. Hauptthemen laut MEDLINE: Mycoplasma genitalium, Mycoplasma Infections, Azithromycin, Drug Resistance, Bacterial. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mycoplasma genitalium (MG) is an emerging sexually transmitted infection, often harboring resistance-associated mutations to azithromycin (AZM). Global surveillance has been mandated to tackle the burden caused by MG, yet no data are available for Austria. Thus, we aimed to investigate the prevalence of MG, disease characteristics, and treatment outcomes at the largest Austrian HIV—and STI clinic.

Methods

All MG test results at the Medical University of Vienna from 02/2019 to 03/2022 were evaluated. Azithromycin resistance testing was implemented in 03/2021.

Results

Among 2671 MG tests, 199 distinct and mostly asymptomatic (68%; 135/199) MG infections were identified, affecting 10% (178/1775) of all individuals. This study included 83% (1479/1775) men, 53% (940/1775) men who have sex with men (MSM), 31% (540/1754) HIV+, and 15% (267/1775) who were using HIV pre-exposure prophylaxis (PrEP). In logistic regression analysis, ‘MSM’ (aOR 2.55 (95% CI 1.65–3.92)), ‘use of PrEP’ (aOR 2.29 (95% CI 1.58–3.32)), and ‘history of syphilis’ (aOR 1.57 (95% CI 1.01–2.24) were independent predictors for MG infections. Eighty-nine percent (178/199) received treatment: 11% (21/178) doxycycline (2 weeks), 52% (92/178) AZM (5 days), and 37% ( 65/178) moxifloxacin (7–10 days) and 60% (106/178) had follow-up data available showing negative tests in 63% (5/8), 76% (44/58) and 85% (34/40), respectively. AZM resistance analysis was available for 57% (114/199)) and detected in 68% (78/114). Resistance-guided therapy achieved a cure in 87% (53/61), yet, empiric AZM-treatment (prior to 03/2021) cleared 68% (26/38).

Conclusions

Mycoplasma genitalium was readily detected in this Austrian observational study, affected predominantly MSM and often presented as asymptomatic disease. We observed a worryingly high prevalence of AZM resistance mutations; however, empiric AZM treatment cleared twice as many MG infections as expected.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycoplasma genitaliumMycoplasma InfectionsAzithromycinDrug Resistance, BacterialAnti-Bacterial AgentsMacrolidesHumansAustriaMaleAdultFemaleMiddle AgedPrevalenceTreatment OutcomeHomosexuality, MaleYoung Adult

Stichwörter der Autor:innen

Mycoplasma genitaliumAzithromycinMacrolide resistanceMen who have sex with men

Substanzen

AzithromycinAnti-Bacterial AgentsMacrolides

Autor:innen und Institutionen

  • Department of Dermatology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
  • Department of Dermatology and Venereology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
  • Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.
  • Division of Clinical Microbiology, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
  • Department of Dermatology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. wolfgang.bauer@meduniwien.ac.at.

Förderung

  • Medical University of Vienna

Zitieren

APA

Chromy, D., Starossek, L., Grabmeier-Pfistershammer, K., Adamek, S., Maischack, F., Sammet, S., Sadoghi, B., Stary, G., Willinger, B., Weninger, W., Esser, S., Makristathis, A., & Bauer, W. M. (2024). High cure rates of Mycoplasma genitalium following empiric treatment with azithromycin alongside frequent detection of macrolide resistance in Austria. Infection, 52(5), 1921-1930. https://doi.org/10.1007/s15010-024-02261-6

Vancouver

Chromy D, Starossek L, Grabmeier-Pfistershammer K, Adamek S, Maischack F, Sammet S, et al. High cure rates of Mycoplasma genitalium following empiric treatment with azithromycin alongside frequent detection of macrolide resistance in Austria. Infection. 2024;52(5):1921-1930. doi:10.1007/s15010-024-02261-6

BibTeX
@article{Chromy2024,
  author = {Chromy, David and Starossek, Lisa and Grabmeier-Pfistershammer, Katharina and Adamek, Sarah and Maischack, Felix and Sammet, Stefanie and Sadoghi, Birgit and Stary, Georg and Willinger, Birgit and Weninger, Wolfgang and Esser, Stefan and Makristathis, Athanasios and Bauer, Wolfgang Michael},
  title = {High cure rates of Mycoplasma genitalium following empiric treatment with azithromycin alongside frequent detection of macrolide resistance in Austria},
  journal = {Infection},
  year = {2024},
  volume = {52},
  number = {5},
  pages = {1921--1930},
  doi = {10.1007/s15010-024-02261-6}
}
Kostenlos starten →